AKTing on XPO1 inhibition in AML
Inhibition of XPO1-mediated nuclear export by selinexor represents a promising therapeutic strategy in acute myeloid leukemia. Because XPO1 is not specific for tumor-suppressive proteins, selinexor may also activate pro-oncogenic processes. A study now shows that inhibition of selinexor-induced, pur...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
26 July 2022
|
| In: |
Nature cancer
Year: 2022, Jahrgang: 3, Heft: 7, Pages: 787-789 |
| ISSN: | 2662-1347 |
| DOI: | 10.1038/s43018-022-00395-w |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s43018-022-00395-w Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s43018-022-00395-w 
|
| Verfasserangaben: | Stefanie Göllner and Carsten Müller-Tidow |
| Zusammenfassung: | Inhibition of XPO1-mediated nuclear export by selinexor represents a promising therapeutic strategy in acute myeloid leukemia. Because XPO1 is not specific for tumor-suppressive proteins, selinexor may also activate pro-oncogenic processes. A study now shows that inhibition of selinexor-induced, purinergic receptor-mediated AKT activation potentiates its anti-leukemic activity. |
|---|---|
| Beschreibung: | Gesehen am 19.08.2022 |
| Beschreibung: | Online Resource |
| ISSN: | 2662-1347 |
| DOI: | 10.1038/s43018-022-00395-w |